Risk of Misdiagnosing Chronic Traumatic Encephalopathy in Men With Depression
Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
Abstract
Objective:
In recent years, it has been proposed that depression represents one clinical subtype of chronic traumatic encephalopathy (CTE). This is the first study to examine the specificity of the research criteria for the clinical diagnosis of CTE in men with depression from the general population.
Methods:
Data from the National Comorbidity Survey Replication, an in-person survey that examined the prevalence and correlates of mental disorders in the United States, were used for this study. Men diagnosed as having a major depressive episode in the past 30 days were included (N=101; mean age=39.4 years, SD=12.9, range=18–71). They were deemed to meet research criteriafor CTE if they presented with the purported supportive clinical features of CTE (e.g., impulsivity and substance abuse, anxiety, apathy, suicidality, and headache).
Results:
Approximately half of the sample (52.5%) met the proposed research criteria for CTE (i.e., traumatic encephalopathy syndrome). If one accepts the delayed-onset criterion as being present, meaning that the men in the sample were presenting with depression years after retirement from sports or the military, then 83.2% of this sample would meet the research criteria for diagnosis.
Conclusions:
The clinical problems attributed to CTE, such as depression, suicidality, anxiety, anger control problems, and headaches, co-occurred in this sample of men with depression from the general population—illustrating that these problems are not specific or unique to CTE. More research is needed to determine whether depression is, in fact, a clinical subtype of CTE.
In the 20th century, chronic traumatic encephalopathy (CTE), also known as dementia pugilistica, was considered a neurological syndrome affecting some active and retired, long-career, high-exposure boxers (1, 2). Cumulative and chronic brain damage (3) was believed to be the underlying neuropathology (4), and varying degrees of slurred or dysarthric speech, abnormalities in gait and coordination, parkinsonism, cognitive deficits, and dementia were emphasized in the literature (1–3). The neurological problems were often described as pyramidal (e.g., abnormal reflexes) and extrapyramidal (tremors and parkinsonian gait disturbance), and both were often first noticed at a young age, in some active boxers, who were in their 20s and 30s (2, 4–11). It was understood that some boxers with chronic brain damage exhibited diverse psychiatric and neurological problems that co-occurred with the above-described characteristic features (2, 5, 10, 12). For example, some authors described euphoria (6, 13); a childlike demeanor (4) or “fatuous cheerfulness” (6); and aggression, volatility, and anger dyscontrol (4–6, 8, 10, 12) as behavioral characteristics, often representing a complex neuropsychiatric presentation. It was unclear whether this neurological syndrome was static or progressive or whether its course represented two distinct conditions (1, 2, 7, 10, 13–18), and it was common for researchers to emphasize that chronic brain damage in boxers manifested in variable ways or as different syndromes (6, 7, 10, 13, 16).
Prior to 2005, depression and suicidality were not considered to be core or defining clinical features of CTE. In the past few years, however, there has been a much greater emphasis on mental health problems, such as depression, anxiety, and suicidality (19–22), as being a possible core clinical feature. Without question, some former amateur and professional contact and collision sport athletes experience mental health problems, such as depression (23–26), and tragically some former professional athletes die by suicide (27–31). There is a risk, however, that former contact and collision sport athletes with primary depression will be misdiagnosed as having CTE. This is problematic because some authors assert that CTE is a distinct (20, 32–35) and unique (32) neurodegenerative disease (20, 32, 34, 36, 37), in the family of tauopathies (21)—and, therefore, assuming that depression is a phenotypic expression of CTE has dire implications for morbidity and mortality.
As of the beginning of 2019, there are no agreed upon clinical diagnostic criteria for CTE, although several sets of criteria have been proposed in the past few years (15, 22, 38, 39). Preliminary proposed research criteria for traumatic encephalopathy syndrome (TES) (22) include three core features of CTE—cognitive, behavioral (i.e., anger dyscontrol), and mood (i.e., depression or hopelessness). These core features are used to define diagnostic subtypes or variants, according to the research criteria. Two supportive features must also be present (i.e., impulsivity, anxiety, apathy, paranoia, suicidality, headache, motor signs, a progressive clinical course, or a delayed onset of symptoms [for example, after retirement from sport]). The TES criteria are being used in several studies as part of a $15.8 million multicenter grant entitled “Diagnostics, Imaging, And Genetics Network for the Objective Study and Evaluation of Chronic Traumatic Encephalopathy” (DIAGNOSE CTE) (National Institute of Neurological Disorders and Stroke grant U01NS093334). In April 2019, the DIAGNOSE CTE research team hosted the First National Institutes of Health Consensus Workshop to Define the Diagnostic Criteria for Traumatic Encephalopathy Syndrome (TES). A major gap in the literature is that there are no published studies related to the specificity of the proposed research criteria for TES/CTE.
The study reported here is the first to examine the research criteria for the clinical diagnosis of TES (22) in men with depression from the general population. We chose to study men with depression because depression has been proposed as a core clinical feature, or subtype, of TES. We hypothesized that a substantial percentage of these men from the general population would meet the proposed research criteria for CTE.
Methods
Participants
Data from the National Comorbidity Survey Replication (NCS-R), conducted between February 2001 and April 2003 (40, 41), were used for this study. The NCS-R examined the prevalence and correlates of mental disorders in the United States (42–44). The survey was conducted in person in the homes of a nationally representative sample of adult respondents (N=9,282, including 4,139 men and 5,143 women) (41). The sample of interest was obtained by applying a filter to the publicly available NCS-R database selecting all male participants meeting criteria for a DSM-IV major depressive episode in the past 30 days (i.e., NCS-R variable name D_MDE30). This filter resulted in the inclusion of 101 men; an incidence rate of 2.4% of all men in the database.
The 101 men had a mean age of 39.4 years (SD=12.9, range=18–71). Race-ethnicity was reported as follows: white, 72.3%, N=73; African American, 10.9%, N=11; Mexican, 5.9%, N=6; Asian, 1.0%, N=1; and all other races, 9.9%, N=10. Their level of education was as follows: 0–11 years, 25.7%, N=26; 12 years, 31.7%, N=32; 13–15 years, 27.7%, N=28; and ≥16 years, 14.9%, N=15. Approximately half the sample was employed (52.5%, N=53), 43.5% (N=44) were not in the labor force, and 4% (N=4) were unemployed. Relationship status was described as follows: married, 43.6%, N=44; never married, 32.7%, N=33; and divorced, separate, or widowed, 23.8%, N=24.
The NCS-R Protocol
The survey was conducted using laptop computer-assisted personal interviews by researchers from the Survey Research Center of the Institute for Social Research at the University of Michigan. The core diagnostic assessment of all respondents (N=9,282) included the following modules: household listing, screening, depression, mania, irritable depression, panic disorder, specific phobia, social phobia, agoraphobia, generalized anxiety disorder, intermittent explosive disorder, suicidality, services, and pharmacoepidemiology. The NCS-R diagnoses are based on the World Mental Health Survey Initiative version of the World Health Organization Composite International Diagnostic Interview, a fully structured lay-administered diagnostic interview that generates both ICD-10-CM (45) and DSM-IV (46) diagnoses. The NCS-R database is publicly available (http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/20240).
Research Criteria for TES
Research criteria for TES (22) include three proposed core features of CTE—cognitive, behavioral (i.e., anger dyscontrol), and mood (i.e., depression or hopelessness). The core feature, or subtype, referred to as mood is defined as follows: “Feeling overly sad, depressed, and/or hopeless, as reported by self or informant, by history of treatment, or by clinician’s report. A formal diagnosis of major depressive disorder or persistent depressive disorder would meet this criterion but is not necessary” (22). We selected a sample of men who definitively would meet this core criterion in that they were diagnosed as having a major depressive episode in the past 30 days. This was done to simulate applying the criteria to a man who might present to a clinic for evaluation or treatment. In addition to meeting criteria for TES, the person must have two or more supportive features (i.e., impulsivity, anxiety, apathy, paranoia, suicidality, headache, motor signs, documented decline in functioning or a progression of symptoms, or a delayed onset—such as having problems at least 2 years after the end of a career in contact sports). For the purposes of this study, we selected five of the nine supportive features, available in the NCS-R database, for the primary analyses (i.e., impulsivity, anxiety, apathy, suicidality, and headache) because paranoia, motor signs, decline in functioning, and delayed onset of symptoms were deemed to be less reliable or missing variables in the NCS-R database.
We present the rates of positive screens for TES in two ways. First, the rate at which the men met two of the five supportive criteria is presented. Second, the rate at which the men met one of the five supportive criteria is presented, because this simulates the assumption that the delayed-onset criterion or the decline in functioning criterion would be met. The delayed-onset criterion requires “delayed onset of clinical features after significant head impact exposure, usually at least 2 years and in many cases several years after the period of maximal exposure,” and the “documented decline” criterion requires a “progressive decline in function and/or a progression in symptoms” (22).
Results
Lifetime experiences with major mental disorders, suicidal ideation and behavior, substance abuse, and headaches for the 101 men with depression are presented in Tables 1 and 2. A substantial minority of the sample reported a lifetime history of alcohol dependence (26.7%), drug abuse (36.6%), and drug dependence (20.8%), and 8%−14% reported experiencing these problems in the past 12 months. A lifetime history of generalized anxiety disorder was reported by 30.7%, 25.7% had the disorder in the past 12 months, and 16.8% met criteria for the disorder in the past 30 days. Serious anger control problems were common in that 34.7% had a lifetime history of DSM-IV intermittent explosive disorder (Table 1), and 23.8% met criteria for the disorder in the past 12 months. More than half (52.5%) reported feeling mad or angry during the past month (Table 2). Suicidal ideation and behavior were also common (Table 2). Approximately 43% had contemplated suicide during their lifetime, and 18.8% had attempted suicide. One in five (20.8%) had seriously considered suicide in the past 12 months. One in four (23.8%) reported a current problem with severe headaches (Table 2).
| Lifetime | Past 12 months | Past 30 days | ||||
|---|---|---|---|---|---|---|
| Disorder | N | % | N | % | N | % |
| Substance use disorder | ||||||
| Alcohol abuse | 49 | 48.5 | 14 | 13.9 | 7 | 6.9 |
| Alcohol dependence | 27 | 26.7 | 10 | 9.9 | 6 | 5.9 |
| Drug abuse | 37 | 36.6 | 14 | 13.9 | 8 | 7.9 |
| Drug dependence | 21 | 20.8 | 8 | 7.9 | 5 | 5.0 |
| Nicotine dependence | 22 | 21.8 | 15 | 14.9 | 12 | 11.9 |
| Intermittent explosive disorder | 35 | 34.7 | 24 | 23.8 | 14 | 13.9 |
| Mood disorder | ||||||
| Dysthymia | 30 | 29.7 | 30 | 29.7 | 30 | 29.7 |
| Major depressive episode | 101 | 100 | 101 | 100 | 101 | 100 |
| Bipolar I disorder | 9 | 8.9 | 9 | 8.9 | 9 | 8.9 |
| Bipolar II disorder | 11 | 10.9 | 11 | 10.9 | 11 | 10.9 |
| Bipolar disorder subthreshold | 7 | 6.9 | 7 | 6.9 | 7 | 6.9 |
| Hypomania | 3 | 3.0 | 3 | 3.0 | 2 | 2.0 |
| Mania | 24 | 23.8 | 19 | 18.8 | 12 | 11.9 |
| Anxiety disorder | ||||||
| Generalized anxiety disorder | 31 | 30.7 | 26 | 25.7 | 17 | 16.8 |
| Panic attack | 61 | 60.4 | 43 | 42.6 | 32 | 31.7 |
| Panic disorder | 21 | 20.8 | 18 | 17.8 | 15 | 14.9 |
| Agoraphobia without panic disorder | 15 | 14.9 | 14 | 13.9 | 11 | 10.9 |
| Agoraphobia with panic disorder | 9 | 8.9 | 8 | 7.9 | 7 | 6.9 |
| Posttraumatic stress disorder | 17 | 16.8 | 11 | 10.9 | 7 | 6.9 |
| Adult separation anxiety disorder | 30 | 29.7 | 17 | 16.8 | 13 | 12.9 |
| Social phobia | 44 | 43.6 | 35 | 34.7 | 23 | 22.8 |
| Specific phobia | 33 | 32.7 | 29 | 28.7 | 26 | 25.7 |
| Adolescent and developmental disorders | ||||||
| Attention-deficit hyperactivity disorder | 17 | 16.8 | 12 | 11.9 | ||
| Conduct disorder | 19 | 18.8 | 3 | 3.0 | ||
| Oppositional defiant disorder | 24 | 23.8 | 3 | 3.0 | ||
| Condition | N | % |
|---|---|---|
| Headaches | ||
| Ever had frequent or severe headaches | 38 | 37.6 |
| Still have severe headache or received treatment | 24 | 23.8 |
| Chronic pain and headaches | ||
| Ever had chronic back or neck problems | 53 | 52.5 |
| Still have back or neck problems or received treatment in past year | 40 | 39.6 |
| Ever had any other chronic pain | 27 | 26.7 |
| Still have chronic pain or received treatment in past year | 24 | 23.8 |
| Ever had arthritis or rheumatism | 28 | 27.7 |
| Anger attacks (ever in life) | ||
| Anger attack leading to breaking item of some value | 64 | 63.4 |
| Anger attack leading to hitting or attempt to hit a person | 46 | 45.5 |
| Irritability and anger in past montha | ||
| Feel irritable or grumpy | 64 | 63.4 |
| Feel mad or angry | 53 | 52.5 |
| Feel angry and out of control | 18 | 17.8 |
| Feel urge to hit, push, or hurt someone | 16 | 15.8 |
| Feel urge to break or smash something | 17 | 16.8 |
| Suicidal ideation and behavior | ||
| Ever seriously thought about committing suicideb | 43 | 42.6 |
| Seriously thought about committing suicide in past 12 months | 21 | 20.8 |
| Ever made a plan for committing suicide | 20 | 19.8 |
| Made a suicide plan in the past 12 months | 7 | 6.9 |
| Ever attempted suicide | 19 | 18.8 |
| Attempted suicide in the past 12 months | 6 | 5.9 |
a
Data were missing for one subject. Those who rated experiencing irritability or anger as some of the time, most of the time, or all of the time were included.
b
Data were missing for 14 subjects (49.4% with complete data endorsed this item as yes).
The percentages of men meeting supportive criteria for TES are presented in Table 3. Impulsivity, as reflected by a diagnosis of alcohol or drug abuse in the past year, was present in 20.8%. Problems with anxiety were present in 73.3%, and suicidality was present in 20.8%. Apathy was reported by 36.6%. A significant problem with headaches was reported by 23.8%. Overall, 52.5% met criteria for two or more supportive features for TES; when their two-criteria status was combined with their diagnosis of depression, these men would meet the clinical criteria for TES. We could not apply the criteria related to delayed onset (e.g., mental health problems in a middle-aged man who played collegiate football or hockey) or to progressive worsening of symptoms (i.e., over at least a 1-year duration). Assuming that one of those criteria were met, then only one additional criterion from Table 3 would be necessary to meet research criteria for the syndrome. The proportion of the sample who met one or more of the criteria was 83.2%.
| Criterion and definition | N | % |
|---|---|---|
| “Impulsivity: Impaired impulse control, as demonstrated by new behaviors, such as excessive gambling, increased or unusual sexual activity, substance abuse, excessive shopping or unusual purchases, or similar activities” (22). Definition: DSM-IV diagnosis of alcohol abuse in past year (D_ALA12) or drug abuse in past year (D_DRA12). | 21 | 20.8 |
| “Anxiety: History of anxious mood, agitation, excessive fears, or obsessive or compulsive behavior (or both), as reported by self or informant, history of treatment, or clinician’s report. A formal diagnosis of anxiety disorder would meet this criterion but is not necessary” (22). Definition: DSM-IV diagnosis, in the past year, of generalized anxiety disorder (D_GAD12), agoraphobia without panic disorder (D_AGO12), agoraphobia with panic disorder (D_AGP12), panic disorder (D_PDS12), social phobia (i.e., social anxiety disorder; D_SO12), posttraumatic stress disorder (D_PTS12), or rating any of the following as 1 (often in the past month): nervousness, fidgety, tense (SC9D); worry too much about things (NSD1F); suddenly scared for no reason (NSD1B); or feel frightened (NSD1H). | 74 | 73.3 |
| “Apathy: Loss of interest in usual activities, loss of motivation and emotions, and/or reduction of voluntary, goal-directed behaviors, as reported by self or informant, history of treatment, or clinician’s report” (22). Definition: No interest in things over the past month (rated as 1 [often]; NSD1G). | 37 | 36.6 |
| “Suicidality: History of suicidal thoughts or attempts, as reported by self or informant, history of treatment, or clinician’s report (22).” Definition: Seriously thought about committing suicide in past 12 months (SD3), made a suicide plan in past 12 months (SD5), or attempted suicide in past 12 months (SD10). | 21 | 20.8 |
| “Headache: Significant and chronic headaches with at least one episode per month for a minimum of 6 months” (22). Definition: Reports a current problem with severe headaches or treatment for headaches (CC4C). | 24 | 23.8 |
| One or more of the above criteria met | 84 | 83.2 |
| Two or more of the above criteria met | 53 | 52.5 |
a
Variable names (e.g., D_ALA12, D_GAD12) from the publicly available National Comorbidity Survey Replication database are provided.
Discussion
This is the first study to examine a proposed set of research criteria for the clinical diagnosis of CTE (22) in a sample of men from the general population who suffer from depression. Depression has emerged in recent years as a proposed core feature and clinical subtype of CTE (19–22). The mean age of the sample used in this study was 39.4 years, and most were between the ages of 26 and 52, with an age range of 18–71. For comparison, the mean age is similar to the age reported as the age at onset of the mood and behavioral symptoms associated with CTE (i.e., mean=34.5 years, SD=11.6, range=19–59 years) (47).
The results were striking in that 52.5% of these men met the proposed research criteria for CTE (i.e., TES). We were unable to study two important secondary criteria, delayed onset and progressive course. If we assume that one of those criteria would be met (i.e., the person developed depression years after playing a sport or years after military service or the person had a worsening of symptoms over the past year), then it would be necessary to meet only one of the five criteria in the present study to screen positive for TES. Under those assumptions, then 83.2% of this sample would meet the research criteria for a clinical diagnosis of CTE.
The clinical problems attributed to CTE (22), such as depression, suicidality, anxiety, anger control problems, and headaches, co-occurred in this sample of men with depression from the general population—illustrating that they are not specific or unique to CTE. These results have important implications. At least 50% of men from the general population, who have depression and are presenting for health care, will appear to have a full complement of symptoms and problems that have been asserted to be characteristic of CTE. For former athletes and military veterans who present many years after retirement and who experienced a documented decline in their mental health, the large majority (i.e., eight out of ten) will meet these research criteria.
We did not examine the exposure criterion (22) in the research definition for TES because a history of participation in contact or collision sports was not included in the NCS-R database. At minimum, the exposure criterion simply requires that the person played sports (e.g., boxing, American football, ice hockey, lacrosse, rugby, wrestling, or soccer) for a minimum of 6 years (with 2 years at the college level [or equivalent] or higher) that resulted in “multiple impacts to the head” that can be concussions or “subconcussive trauma” (i.e., with no clinical symptoms) (22). Military service or police training involving exposure to blasts, explosives, combat, or breaching also is listed as a source of exposure sufficient to meet criteria. Therefore, if the presenting male patient was a former athlete or military veteran, there might be an assumption by the health care provider that he meets the exposure threshold for repetitive mild neurotrauma and that his depressive disorder (with supportive features) is a clinical manifestation of a presumed neurodegenerative disease versus being caused or amplified by a diverse range of other biopsychosocial factors. This has critical implications for the doctor-patient relationship, information provided to the patient and family, prognosis, and recommended course of treatment.
According to the research criteria for TES (22), all former professional soccer players, hockey players, boxers, and American or Canadian football players meet the exposure criteria for repetitive neurotrauma. Careful examination of the criteria reveal that an extraordinarily broad range of psychiatric and neurological presentations from these former athletes could meet the clinical criteria for the syndrome, including the following ten examples: depression, suicidality, and headaches; depression, anxiety, and headaches; depression, anxiety, and substance abuse; depression, posttraumatic stress disorder, and headaches; anger control problems, depression, and anxiety; anger control problems, substance abuse, and suicidality; mild cognitive impairment, anxiety, and substance abuse; Parkinson’s disease or parkinsonism, mild cognitive impairment, and apathy; Alzheimer’s disease, apathy, and paranoia; and frontotemporal dementia, impulsivity, and paranoia. Each of the ten examples includes three clinical problems—a core feature and two supportive features. However, only one supportive feature is required if the person meets the delayed-onset supportive criterion. For example, if a person was healthy in his or her 20s and developed depression and headaches during his or her 30s or 40s, that person would meet the core and supportive criteria for TES. This is clearly problematic in that people presenting with an extraordinarily broad range of psychiatric and neurological problems could be diagnosed, and misdiagnosed, as having TES/CTE.
Our study has three important limitations. First, it is possible, in fact likely, that some of the men in our case series experienced one or more concussions during the course of their lives. Concussions are very common in men in the general population. Second, it is likely that some of them played contact sports, at least briefly, during their lives. No information related to lifetime history of sports participation was available in the database. Third, we were not able to map the results of the NCS-R interviews precisely on to the research criteria for CTE. If we had more variables that aligned with the criteria, the rate of presumed misdiagnosis of the syndrome would have been greater. The obvious strength of the study is that the men were selected from a nationally representative sample of men from the U.S. general population who underwent a thorough in-person psychiatric interview yielding DSM-IV diagnoses, and this database has been used for many studies that have advanced knowledge regarding mental health problems in the U.S. population (42–44).
Conclusions
We conclude with four important points. First, CTE is a postmortem neuropathological diagnosis (21, 48), with the preliminary proposed defining pathological feature being the accumulation of hyperphosphorylated tau (p-tau), in a patchy distribution at the depths of the cortical sulci around small vessels (21, 48). In normal aging and in neurodegenerative diseases, p-tau accumulates in the brain (49–52), but it is not believed to accumulate in a patchy distribution in the depths of sulci in association with aging or other diseases (21, 48). The pathology has been identified after death in the brains of young athletes (30, 35), military veterans (53), active NFL players (30, 35), former collegiate athletes from multiple sports (35), retired boxers (35), retired professional hockey players (35), and retired NFL players (21, 30, 35). However, the neuropathology described as unique to CTE may not be completely unique because it has also been identified in some individuals with no known exposure to repetitive neurotrauma, in association with substance abuse, temporal lobe epilepsy, amyotrophic lateral sclerosis, multiple system atrophy, and other neurodegenerative diseases (54–60).
Second, the extent to which the neuropathology is associated with, or causes, specific clinical symptoms and problems is unclear (48, 61). Third, it has not been established that depression arises from the neuropathology of CTE, and depression was not considered to be a core clinical feature of CTE prior to 2005. Depression was reported in some historical cases (5, 8, 10, 12, 62), but it was usually reported in the context of boxers having more characteristic and obvious neurological problems (as opposed to a primary presentation of depression). It is well established in the literature that people who sustain a single traumatic brain injury, of any severity, are at increased risk of developing depression (63–65), and it is possible that cumulative very mild neurotrauma, acquired over the course of many years of exposure, could increase a person’s risk of developing depression—but this has not been established in the literature. Depression in adults is linked to genetics (66), adverse events in childhood (67, 68), and, of course, current life stressors (69). Moreover, numerous health conditions are associated with increased risk of depression, such as chronic pain (70), headaches and migraines (71, 72), chronic insomnia (73), and sleep apnea (74). Later-in-life neurological diseases also are associated with depression, including mild cognitive impairment (75), Parkinson’s disease (76), and Alzheimer’s disease (77).
Fourth, it is essential to appreciate that many of the mental health, physical, and psychosocial problems that have been attributed to CTE in the recent literature are fairly common in men in the general population (78), they are very common in men with depression, and they tend to co-occur both in the general population and in men with depression. As noted in the DSM-5, individuals with depression often have considerable problems with irritability (e.g., persistent anger, a tendency to respond to events with angry outbursts or blaming others, and an exaggerated sense of frustration over minor matters), and family members often notice social withdrawal. Men with depression have higher rates of anger attacks and aggression, substance abuse, and risk taking (79).
Researchers have not established a clinicopathological correlation between depression and the region-specific accumulation of hyperphosphorylated tau believed to characterize CTE (48), and thus researchers and clinicians should not assume, uncritically, that depression in a former athlete or military veteran is caused or amplified by CTE neuropathology. More research is needed to determine whether depression is, in fact, a clinical subtype of CTE.
Footnotes
The Baseline National Comorbidity Survey Replication data used for this study are available as a public use data set through the Inter-university Consortium for Political and Social Research (ICPSR). The authors acknowledge that the original collector of the data, ICPSR, and the relevant funding agency bear no responsibility for use of the data or for interpretations or inferences based on such uses.
Dr. Iverson has received salary support from the Harvard Integrated Program to Protect and Improve the Health of National Football League Players Association Members; he has served as a scientific advisor to BioDirection, Highmark, and Sway Operations; he has received research grant support from CNS Vital Signs, ImPACT Applications, the National Football League, and Psychological Assessment Resources; and he has received unrestricted philanthropic support from the Heinz Family Foundation, ImPACT Applications, and the Mooney-Reed Charitable Foundation. Dr. Gardner has served as a contracted concussion consultant to Rugby Australia; he has received travel funding from the Australian Football League; he has received research grant support from Brain Foundation (Australia), the Hunter Medical Research Institute, and the New South Wales Sporting Injuries Committee; he currently receives funding from the Australian-American Fulbright Commission, the Priority Research Centre for Stroke and Brain Injury at the University of Newcastle, and the Research, Innovation and Partnerships Health Research and Translation Centre and Clinical Research Fellowship Scheme of the Hunter New England Local Health District; and he has a clinical and consulting practice in forensic neuropsychology, including expert testimony, involving individuals who have sustained mild traumatic brain injuries (including athletes).
References
1.
Martland HS: Punch drunk. J Am Med Assoc 1928; 19:1103–1107
2.
Roberts A: Brain Damage in Boxers: A Study of Prevalence of Traumatic Encephalopathy Among Ex-Professional Boxers. London, Pitman Medical Scientific Publishing, 1969
3.
Jordan BD: Chronic traumatic brain injury associated with boxing. Semin Neurol 2000; 20:179–185
4.
Corsellis JA, Bruton CJ, Freeman-Browne D: The aftermath of boxing. Psychol Med 1973; 3:270–303
5.
Mawdsley C, Ferguson FR: Neurological disease in boxers. Lancet 1963; 2:795–801
6.
Critchley M: Medical aspects of boxing, particularly from a neurological standpoint. BMJ 1957; 1:357–362
7.
Parker HL: Traumatic encephalopathy (“punch drunk”) of professional pugilists. J Neurol Psychopathol 1934; 15:20–28
8.
Harvey PK, Davis JN: Traumatic encephalopathy in a young boxer. Lancet 1974; 2:928–929
9.
Jedliński J, Gatarski J, Szymusik A: Chronic posttraumatic changes in the central nervous system in pugilists. Pol Med J 1970; 9:743–752
10.
Johnson J: Organic psychosyndromes due to boxing. Br J Psychiatry 1969; 115:45–53
11.
Sercl M, Jaros O: The mechanisms of cerebral concussion in boxing and their consequences. World Neurol 1962; 3:351–358
12.
Payne EE: Brains of boxers. Neurochirurgia 1968; 11:173–188
13.
Critchley M: Punch-drunk syndromes: the chronic traumatic encephalopathy of boxers, in Neuro-chirurgie; Hommage a Clovis Vincent. Paris, Maloine, 1949
14.
Carrol EJ: Punch-drunk. Am J Med Sci 1936; 191:706–712
15.
Victoroff J: Traumatic encephalopathy: review and provisional research diagnostic criteria. NeuroRehabilitation 2013; 32:211–224
16.
Courville CB: Punch drunk: its pathogenesis and pathology on the basis of a verified case. Bull Los Angel Neuro Soc 1962; 27:160–168
17.
Grahmann H, Ule G: Diagnosis of chronic cerebral symptoms in boxers (dementia pugilistica and traumatic encephalopathy of boxers [in German]. Psychiatr Neurol 1957; 134:261–283
18.
Mendez MF: The neuropsychiatric aspects of boxing. Int J Psychiatry Med 1995; 25:249–262
19.
Omalu B, Bailes J, Hamilton RL, et al: Emerging histomorphologic phenotypes of chronic traumatic encephalopathy in American athletes. Neurosurgery 2011; 69:173–183, discussion 183
20.
Baugh CM, Stamm JM, Riley DO, et al: Chronic traumatic encephalopathy: neurodegeneration following repetitive concussive and subconcussive brain trauma. Brain Imaging Behav 2012; 6:244–254
21.
McKee AC, Stern RA, Nowinski CJ, et al: The spectrum of disease in chronic traumatic encephalopathy. Brain 2013; 136:43–64
22.
Montenigro PH, Baugh CM, Daneshvar DH, et al: Clinical subtypes of chronic traumatic encephalopathy: literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome. Alzheimers Res Ther 2014; 6:68
23.
Kerr ZY, DeFreese JD, Marshall SW: Current physical and mental health of former collegiate athletes. Orthop J Sports Med 2014; 2:2325967114544107
24.
Kerr ZY, Marshall SW, Harding HP Jr, et al: Nine-year risk of depression diagnosis increases with increasing self-reported concussions in retired professional football players. Am J Sports Med 2012; 40:2206–2212
25.
Guskiewicz KM, Marshall SW, Bailes J, et al: Recurrent concussion and risk of depression in retired professional football players. Med Sci Sports Exerc 2007; 39:903–909
26.
Casson IR, Viano DC, Haacke EM, et al: Is there chronic brain damage in retired NFL players? Neuroradiology, neuropsychology, and neurology examinations of 45 retired players. Sports Health 2014; 6:384–395
27.
Baron SL, Hein MJ, Lehman E, et al: Body mass index, playing position, race, and the cardiovascular mortality of retired professional football players. Am J Cardiol 2012; 109:889–896
28.
Lehman EJ, Hein MJ, Gersic CM: Suicide mortality among retired National Football League players who played 5 or more seasons. Am J Sports Med 2016; 44:2486–2491
29.
Webner D, Iverson GL: Suicide in professional American football players in the past 95 years. Brain Inj 2016; 30:1718–1721
30.
Mez J, Daneshvar DH, Kiernan PT, et al: Clinicopathological evaluation of chronic traumatic encephalopathy in players of American football. JAMA 2017; 318:360–370
31.
Gouttebarge V, Ooms W, Tummers T, et al: Mortality in international professional football (soccer): a descriptive study. J Sports Med Phys Fitness 2015; 55:1376–1382
32.
Baugh CM, Robbins CA, Stern RA, et al: Current understanding of chronic traumatic encephalopathy. Curr Treat Options Neurol 2014; 16:306
33.
Gavett BE, Stern RA, McKee AC: Chronic traumatic encephalopathy: a potential late effect of sport-related concussive and subconcussive head trauma. Clin Sports Med 2011; 30:179–188
34.
Mez J, Stern RA, McKee AC: Chronic traumatic encephalopathy: where are we and where are we going? Curr Neurol Neurosci Rep 2013; 13:407
35.
McKee AC, Cantu RC, Nowinski CJ, et al: Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol 2009; 68:709–735
36.
Gavett BE, Cantu RC, Shenton M, et al: Clinical appraisal of chronic traumatic encephalopathy: current perspectives and future directions. Curr Opin Neurol 2011; 24:525–531
37.
McKee AC, Daneshvar DH, Alvarez VE, et al: The neuropathology of sport. Acta Neuropathol 2014; 127:29–51
38.
Jordan BD: The clinical spectrum of sport-related traumatic brain injury. Nat Rev Neurol 2013; 9:222–230
39.
Reams N, Eckner JT, Almeida AA, et al: A clinical approach to the diagnosis of traumatic encephalopathy syndrome: a review. JAMA Neurol 2016; 73:743–749
40.
Kessler RC, Merikangas KR: The National Comorbidity Survey Replication (NCS-R): background and aims. Int J Methods Psychiatr Res 2004; 13:60–68
41.
Kessler RC, Berglund P, Chiu WT, et al: The US National Comorbidity Survey Replication (NCS-R): design and field procedures. Int J Methods Psychiatr Res 2004; 13:69–92
42.
Kessler RC, Berglund P, Demler O, et al: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289:3095–3105
43.
Kessler RC, Brandenburg N, Lane M, et al: Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication. Psychol Med 2005; 35:1073–1082
44.
Borges G, Angst J, Nock MK, et al: A risk index for 12-month suicide attempts in the National Comorbidity Survey Replication (NCS-R). Psychol Med 2006; 36:1747–1757
45.
International Statistical Classification of Diseases and Related Health Problems, 10th ed. Geneva, World Health Organization, 1992
46.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, American Psychiatric Association, 1994
47.
Stern RA, Daneshvar DH, Baugh CM, et al: Clinical presentation of chronic traumatic encephalopathy. Neurology 2013; 81:1122–1129
48.
McKee AC, Cairns NJ, Dickson DW, et al: The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol 2016; 131:75–86
49.
Braak H, Thal DR, Ghebremedhin E, et al: Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011; 70:960–969
50.
Kovacs GG, Ferrer I, Grinberg LT, et al: Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol 2016; 131:87–102
51.
Crary JF, Trojanowski JQ, Schneider JA, et al: Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 2014; 128:755–766
52.
Morsch R, Simon W, Coleman PD: Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 1999; 58:188–197
53.
Goldstein LE, Fisher AM, Tagge CA, et al: Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. Sci Transl Med 2012; 4:134ra60
54.
Noy S, Krawitz S, Del Bigio MR: Chronic traumatic encephalopathy-like abnormalities in a routine neuropathology service. J Neuropathol Exp Neurol 2016; 75:1145–1154
55.
Ling H, Holton JL, Shaw K, et al: Histological evidence of chronic traumatic encephalopathy in a large series of neurodegenerative diseases. Acta Neuropathol 2015; 130:891–893
56.
Puvenna V, Engeler M, Banjara M, et al: Is phosphorylated tau unique to chronic traumatic encephalopathy? Phosphorylated tau in epileptic brain and chronic traumatic encephalopathy. Brain Res 2016; 1630:225–240
57.
Fournier CN, Gearing M, Upadhyayula SR, et al: Head injury does not alter disease progression or neuropathologic outcomes in ALS. Neurology 2015; 84:1788–1795
58.
Gao AF, Ramsay D, Twose R, et al: Chronic traumatic encephalopathy-like neuropathological findings without a history of trauma. Int J Pathol Clin Res 2017; 3:050
59.
Koga S, Dickson DW, Bieniek KF: Chronic traumatic encephalopathy pathology in multiple system atrophy. J Neuropathol Exp Neurol 2016; 75:963–970
60.
Iverson GL, Luoto TM, Karhunen PJ, et al: Mild chronic traumatic encephalopathy neuropathology in people with no known participation in contact sports or history of repetitive neurotrauma. J Neuropathol Exp Neurol 2019; 78:615–625
61.
Iverson GL, Keene CD, Perry G, et al: The need to separate chronic traumatic encephalopathy neuropathology from clinical features. J Alzheimers Dis 2018; 61:17–28
62.
Spillane JD: Five boxers. BMJ 1962; 2:1205–1210
63.
Deb S, Lyons I, Koutzoukis C: Neuropsychiatric sequelae one year after a minor head injury. J Neurol Neurosurg Psychiatry 1998; 65:899–902
64.
Jorge RE, Robinson RG, Moser D, et al: Major depression following traumatic brain injury. Arch Gen Psychiatry 2004; 61:42–50
65.
Levin HS, Brown SA, Song JX, et al: Depression and posttraumatic stress disorder at three months after mild to moderate traumatic brain injury. J Clin Exp Neuropsychol 2001; 23:754–769
66.
Sullivan PF, Neale MC, Kendler KS: Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000; 157:1552–1562
67.
Bradley RG, Binder EB, Epstein MP, et al: Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry 2008; 65:190–200
68.
Heim C, Newport DJ, Mletzko T, et al: The link between childhood trauma and depression: insights from HPA axis studies in humans. Psychoneuroendocrinology 2008; 33:693–710
69.
Kendler KS, Karkowski LM, Prescott CA: Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry 1999; 156:837–841
70.
Fishbain DA, Cutler R, Rosomoff HL, et al: Chronic pain-associated depression: antecedent or consequence of chronic pain? A review. Clin J Pain 1997; 13:116–137
71.
Breslau N, Schultz LR, Stewart WF, et al: Headache and major depression: is the association specific to migraine? Neurology 2000; 54:308–313
72.
Breslau N, Lipton RB, Stewart WF, et al: Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology 2003; 60:1308–1312
73.
Ohayon MM, Lemoine P: Daytime consequences of insomnia complaints in the French general population [in French]. Encephale 2004; 30:222–227
74.
Garbarino S, Bardwell WA, Guglielmi O, et al: Association of anxiety and depression in obstructive sleep apnea patients: a systematic review and meta-analysis. Behav Sleep Med (Epub ahead of print Nov 19, 2018)
75.
Barnes DE, Alexopoulos GS, Lopez OL, et al: Depressive symptoms, vascular disease, and mild cognitive impairment: findings from the Cardiovascular Health Study. Arch Gen Psychiatry 2006; 63:273–279
76.
Djamshidian A, Friedman JH: Anxiety and depression in Parkinson’s disease. Curr Treat Options Neurol 2014; 16:285
77.
Raskind MA: Diagnosis and treatment of depression comorbid with neurologic disorders. Am J Med 2008; 121(suppl 2):S28–S37
78.
Iverson GL, Terry DP, Luz M, et al: Anger and depression in middle-aged men: implications for a clinical diagnosis of chronic traumatic encephalopathy. J Neuropsychiatry Clin Neurosci (Epub ahead of print Apr 25, 2019)
79.
Martin LA, Neighbors HW, Griffith DM: The experience of symptoms of depression in men vs women: analysis of the National Comorbidity Survey Replication. JAMA Psychiatry 2013; 70:1100–1106
Information & Authors
Information
Published In
History
Received: 19 January 2019
Revision received: 19 May 2019
Accepted: 17 June 2019
Published online: 7 October 2019
Published in print: Spring 2020
Keywords
Authors
Funding Information
Supported in part by a National Health and Medical Research Council Early Career Fellowship and Fulbright Fellowship (to Dr. Gardner) and a grant from the National Football League for a program of research titled “The Spectrum of Concussion: Predictors of Clinical Recovery, Treatment and Rehabilitation, and Possible Long-Term Effects” (to Drs. Iverson and Gardner), as well as by unrestricted philanthropic support from ImPACT Applications, the Mooney-Reed Charitable Foundation, and the Spaulding Research Institute.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).